Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Inclusion Criteria

• Provide written informed consent.
• 18 years old or older.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
• Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.

Exclusion Criteria

• Subject's cancer has a known oncogenic driver alteration other than EGFR.
• Known EGFR mutations that cause resistance to osimertinib
• Known human epidermal growth factor receptor 2 (HER2) overexpression
• Any contraindications to treatment with osimertinib